Abstract Body

Background

People with HIV (PWH) are at increased risk of co-infection with hepatitis B virus (HBV). With the increasing use of antiretroviral regimens that lack anti-HBV activity, the risk of HBV reactivation has become a renewed concern. Occult HBV infection is particularly difficult to identify in patients with isolated anti-HBc, as conventional serological markers often fail to capture residual viral activity. High-sensitivity HB core-related antigen (iTACT-HBcrAg) can be detected in HBV-monoinfected patients even after functional cure (HBsAg clearance). Therefore iTACT-HBcrAg may be useful for predicting HBV reactivation in PWH, although evidence in this population remains limited.

Methods

We performed a retrospective study of PWH attending our clinic between January 2023 and March 2024. A total of 550 individuals were tested for HBV serological markers. iTACT-HBcrAg, an ultrasensitive immunoassay for HB-core-related proteins (HBcAg, HBeAg, and p22Cr) was measured in 243 anti-HBc-positive PWH. The cutoff value was set at 2.1 log IU/mL. Clinical and laboratory parameters, including HBsAg, HBsAb, HBV DNA, liver function tests, CD4 count, and treatment history, were compared according to iTACT-HBcrAg status. (IRB approval: IMSUT-IRB 2022-48-1128)

Results

Overall, 55.0% of PWH had evidence of past or current HBV infection, comprising 54.4% with anti-HBc and 4.0% with HBsAg. Among 243 anti-HBc–positive individuals, 7.4% (18/243) tested positive for iTACT-HBcrAg. Of these, 77.8% (14/18) were HBsAg positive, while the remainder were HBsAg negative. 94.4% (17/18) were HBV-DNA negative. Notably, iTACT-HBcrAg was detected in two cases with isolated anti-HBc (HBsAg–/HBsAb–) and in two additional cases with concomitant anti-HBc and HBsAb (128.62 and 44.5mIU/mL). 

Conclusions

A subset of anti-HBc–positive PWH harbored detectable HBV viral protein activity despite negative HBsAg, with four cases of occult HBV infection identified by iTACT-HBcrAg. These findings underscore the potential risk of HBV reactivation in patients receiving antiretroviral therapy without HBV-active agents. iTACT-HBcrAg testing may provide important guidance for antiretroviral therapy selection and for long-term risk stratification and preventive strategies in this population.